Floatz logo

OXALIPLATIN

High Grade B-Cell Lymphoma

City of Hope Medical CenterSmall moleculePhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

84 Active assets in the High Grade B-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Ifosfamide
University of California, Davis
Phase 3BB
ETOPOSIDE
University of Washington
Phase 3BB
DOXORUBICIN
National Cancer Institute (NCI)
Phase 3BB
PREDNISONE TABLETS
National Cancer Institute (NCI)
Phase 3BB
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3BB

View all 50 →

Same molecule, other indications

OXALIPLATIN is also rated in:

exocrine pancreatic carcinomaActive
BBB
Indicative · Phase 2/3
78 / 100
View asset →
colon adenocarcinomaActive
BBB
Indicative · Phase 3
77 / 100
View asset →
rectal cancerActive
BBB
Indicative · Phase 3
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →